Enlarge / Wegovy is an injectable prescription weight reduction drugs that has helped individuals with weight problems. (credit score: Getty | Michael Siluk)
A big, long-term trial of the weight-loss treatment Wegovy (semaglutide) discovered that folks tended to shed pounds over the primary 65 weeks on the drug—about one 12 months and three months—however then hit a plateau or “set level.” However that early weight reduction was typically maintained for as much as 4 years whereas individuals continued taking the weekly injections.
The findings, revealed Monday in Nature Medication, come from a recent evaluation of knowledge from the SELECT trial, which was designed to have a look at the drug’s results on cardiovascular well being. The trial—a multicenter, double-blind, randomized, placebo-controlled path—particularly enrolled individuals with present heart problems who additionally had chubby or weight problems, however didn’t have diabetes. In all, the trial included 17,604 individuals from 41 nations. Seventy-two % of them have been male, 84 % have been white, and the common age was about 62 years previous.
Final 12 months, researchers revealed the trial’s major outcomes, which confirmed that semaglutide diminished members’ threat of coronary heart assault, stroke, and cardiovascular-related deaths by 20 % over the span of just a little over three years.
Learn 5 remaining paragraphs | Feedback
